Phase 2 Clinical Trials

Investigational Influenza Vaccine Phase 2 Results Expected

Investigational Influenza Vaccine • Influenza,Human

Iopofosine I 131 single dose Phase 2 Results Expected

Iopofosine I 131 single dose • Waldenstrom Macroglobulinemia

SAR444200 Phase 2 Results Expected

SAR444200 • Neoplasm

Investigational COVID-19 Vaccine Phase 2 Results Expected

Investigational COVID-19 Vaccine • Influenza

pembrolizumab (KEYTRUDA®) Phase 2 Results Expected

pembrolizumab (KEYTRUDA®) • Melanoma Metastatic

IV Decitabine Phase 2 Results Expected

IV Decitabine • Myelodysplastic Syndromes

Placebo Phase 2 Results Expected

Placebo • Indolent Systemic Mastocytosis

INCB099280 Phase 2 Results Expected

INCB099280 • Advanced Solid Tumor

BLU-808 Phase 2 Results Expected

BLU-808 • Chronic Inducible Urticaria

ADX-629 Phase 2 Results Expected

ADX-629 • Ethanol Intoxication

Itacitinib Phase 2 Results Expected

Itacitinib • MPN (Myeloproliferative Neoplasms)

Osimertinib Phase 2 Results Expected

Osimertinib • Lung Cancer

TNG260 Phase 2 Results Expected

TNG260 • Non Small Cell Lung Cancer

Narazaciclib Phase 2 Results Expected

Narazaciclib • Endometrioid Endometrial Cancer

Rosnilimab Phase 2 Results Expected

Rosnilimab • Rheumatoid Arthritis

Placebo Phase 2 Results Expected

Placebo • Atopic Dermatitis

CLN-081 Phase 2 Results Expected

CLN-081 • Non Small Cell Lung Cancer

LB54640 Phase 2 Results Expected

LB54640 • Hypothalamic Obesity

Ruxolitinib Phase 2 Results Expected

Ruxolitinib • MPN (Myeloproliferative Neoplasms)

Berubicin Phase 2 Results Expected

Berubicin • Glioblastoma Multiforme, Adult

Asparaginase Erwinia Chrysanthemi Phase 2 Results Expected

Asparaginase Erwinia Chrysanthemi • Leukemia

SAR443122 Phase 2 Results Expected

SAR443122 • Colitis Ulcerative

VIR-2218 Phase 2 Results Expected

VIR-2218 • Hepatitis B, Chronic

Placebo for Navepegritide Phase 2 Results Expected

Placebo for Navepegritide • Achondroplasia

Daridorexant 25 mg Phase 2 Results Expected

Daridorexant 25 mg • Insomnia

Daridorexant 10 mg Phase 2 Results Expected

Daridorexant 10 mg • Insomnia Disorder

AVTX-009 Regimen 1 Phase 2 Results Expected

AVTX-009 Regimen 1 • Hidradenitis Suppurativa

Allocetra Phase 2 Results Expected

Allocetra • Osteoarthritis, Knee

BNT164a1 Phase 2 Results Expected

BNT164a1 • Tuberculosis

Tebapivat Phase 2 Results Expected

Tebapivat • Myelodysplastic Syndromes

MCLA-129 Phase 2 Results Expected

MCLA-129 • Non-Small Cell Lung Cancer Metastatic

Navepegritide Phase 2 Results Expected

Navepegritide • Achondroplasia

E7389-LF Phase 2 Results Expected

E7389-LF • Solid Neoplasms

SAT-3247 Phase 2 Results Expected

SAT-3247 • Duchenne Muscular Dystrophy

Tisotumab Vedotin Phase 2 Results Expected

Tisotumab Vedotin • Cervical Cancer

E7090 Phase 2 Results Expected

E7090 • Cholangiocarcinoma

Sarilumab SAR153191 (REGN88) Phase 2 Results Expected

Sarilumab SAR153191 (REGN88) • Juvenile Idiopathic Arthritis

Briquilimab Phase 2 Results Expected

Briquilimab • Chronic Spontaneous Urticaria

retifanlimab Phase 2 Results Expected

Retifanlimab • Metastatic Merkel Cell Carcinoma

INCAGN02385 Phase 2 Results Expected

INCAGN02385 • Endometrial Cancer

epacadostat Phase 2 Results Expected

Epacadostat • Lung Cancer

pemigatinib Phase 2 Results Expected

Pemigatinib • Non-Small Cell Lung Cancer (NSCLC)

Fasedienol Nasal Spray - Placebo Nasal Spray Phase 2 Results Expected

Fasedienol Nasal Spray - Placebo Nasal Spray • Social Anxiety Disorder

efzofitimod 450 mg Phase 2 Results Expected

efzofitimod 450 mg • Interstitial Lung Disease

Selinexor 60 mg Phase 2 Results Expected

Selinexor 60 mg • Myelofibrosis

Bimagrumab Phase 2 Results Expected

Bimagrumab • Obesity

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 Phase 2 Results Expected

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 • Influenza

certepetide Phase 2 Results Expected

certepetide • Cholangiocarcinoma

Ensifentrine 3 mg Phase 2 Results Expected

Ensifentrine 3 mg • Chronic Obstructive Pulmonary Disease

Glycopyrrolate 21.25 mcg Phase 2 Results Expected

Glycopyrrolate 21.25 mcg • Chronic Obstructive Pulmonary Disease

VX-993 Phase 2 Results Expected

VX-993 • Acute Pain

BIIB122 225 mg Phase 2 Results Expected

BIIB122 225 mg • Parkinson Disease

Pregabalin Phase 2 Results Expected

Pregabalin • Diabetic Peripheral Neuropathic Pain

enfortumab vedotin (EV) Phase 2 Results Expected

enfortumab vedotin (EV) • Carcinoma, Transitional Cell

HMPL-760 planned dose 1 Phase 2 Results Expected

HMPL-760 planned dose 1 • Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Tebapivat Phase 2 Results Expected

Tebapivat • Myelodysplastic Syndromes

Tebapivat Matched Placebo Phase 2 Results Expected

Tebapivat Matched Placebo • Sickle Cell Disease

RP-L102 Phase 2 Results Expected

RP-L102 • Fanconi Anemia Complementation Group A

TNG462 Phase 2 Results Expected

TNG462 • Locally Advanced Solid Tumor

Oral MRT-2359 Phase 2 Results Expected

Oral MRT-2359 • NSCLC

Brensocatib Phase 2 Results Expected

Brensocatib • Hidradenitis Suppurativa

rF1V-1018 Phase 2 Results Expected

rF1V-1018 • Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

VX-264 Phase 2 Results Expected

VX-264 • Type 1 Diabetes

Vibostolimab/Pembrolizumab Phase 2 Results Expected

Vibostolimab/Pembrolizumab • Carcinoma, Renal Cell

Pembrolizumab/Quavonlimab Phase 2 Results Expected

Pembrolizumab/Quavonlimab • Colorectal Cancer

Lenvatinib Phase 2 Results Expected

Lenvatinib • Non-small Cell Lung Cancer

Favezelimab/Pembrolizumab Phase 2 Results Expected

favezelimab/pembrolizumab • Hodgkin Lymphoma

Belzutifan Phase 2 Results Expected

Belzutifan • Renal Cell Carcinoma

Pembrolizumab Phase 2 Results Expected

pembrolizumab • Non-small Cell Lung Cancer

Adagrasib oral dose of 400 mg twice daily tablets Phase 2 Results Expected

Adagrasib oral dose of 400 mg twice daily tablets • Advanced NSCLC

CID-103 Phase 2 Results Expected

CID-103 • Chronic Immune Thrombocytopenia

0.5 mg epinephrine Phase 2 Results Expected

0.5 mg epinephrine • Urticaria Chronic

Volixibat Phase 2 Results Expected

Volixibat • Primary Biliary Cholangitis

Placebo Phase 2 Results Expected

Placebo • Alagille Syndrome

ICS-LABA Phase 2 Results Expected

ICS-LABA • Moderate to Severe Asthma

LY3305677 Phase 2 Results Expected

LY3305677 • Obesity

LY3848575 Phase 2 Results Expected

LY3848575 • Neuropathic Pain

LY3841136 Phase 2 Results Expected

LY3841136 • Obesity

Placebo Phase 2 Results Expected

Placebo • Urticaria

ARQ-151 cream 0.05% Phase 2 Results Expected

ARQ-151 cream 0.05% • Atopic Dermatitis (Eczema)

Pegtibatinase Phase 2 Results Expected

Pegtibatinase • Homocystinuria

povorcitinib Phase 2 Results Expected

Povorcitinib • NonSegmental Vitiligo

EDG-7500 Phase 2 Results Expected

EDG-7500 • Hypertrophic Cardiomyopathy

SPY001 Phase 2 Results Expected

SPY001 • Ulcerative Colitis

itacitinib Phase 2 Results Expected

Itacitinib • MPN (Myeloproliferative Neoplasms)

WVE-N531 Phase 2 Results Expected

WVE-N531 • Duchenne Muscular Dystrophy

Rescue medication Phase 2 Results Expected

Rescue medication • Non-Muscle Invasive Bladder Cancer

MRTX0902 Phase 2 Results Expected

MRTX0902 • Solid Tumor

Sacituzumab tirumotecan Phase 2 Results Expected

Sacituzumab tirumotecan • Colorectal Cancer

INCA034176 Phase 2 Results Expected

INCA034176 • Chronic Graft-versus-host-disease

Raludotatug Deruxtecan (R-DXd) Phase 2 Results Expected

Raludotatug Deruxtecan (R-DXd) • Gastrointestinal Cancer

SAR441344 IV Phase 2 Results Expected

SAR441344 IV • Systemic Lupus Erythematosus

REC-4881 Phase 2 Results Expected

REC-4881 • AXIN1 Gene Mutation

Placebo Phase 2 Results Expected

Placebo • Familial Adenomatous Polyposis

Nirogacestat Phase 2 Results Expected

Nirogacestat • Ovarian Granulosa-Stromal Tumor

povetacicept Phase 2 Results Expected

Povetacicept • Lupus Nephritis

SION-719 Phase 2 Results Expected

SION-719 • Cystic Fibrosis (CF)

Halneuron Phase 2 Results Expected

Halneuron • Chemotherapy Induced Neuropathic Pain

INCB099280 Phase 2 Results Expected

INCB099280 • Advanced Solid Tumor

Adagrasib Phase 2 Results Expected

Adagrasib • Carcinoma, Non-Small-Cell Lung